Cataract 45 (CTRCT45) Cell Models for Research

Cataract is the leading cause of blindness worldwide, accounting for approximately 51% of global blindness (WHO, 2023). Age-related cataract affects over 94 million people, with a projected increase due to aging populations. Congenital cataracts, though less common (1-6 per 10,000 live births), are a significant cause of childhood visual impairment. Cataract 45 (CTRCT45) is a rare form of congenital cataract with autosomal dominant inheritance, characterized by bilateral opacities that often require early surgical intervention. The clinical impact includes lifelong visual disability, reduced quality of life, and economic burden. Surgical treatment is effective but not universally accessible, and genetic forms like CTRCT45 highlight the need for targeted therapies.

CTRCT45 provides an excellent model for studying lens development and protein homeostasis. The disease is monogenic, with mutations in the CRYAA gene (encoding alpha-crystallin A) identified as a cause. This simplicity allows precise genetic manipulation to dissect molecular pathways. Public datasets, such as those from the Lens Expression Database and GEO, provide transcriptomic and proteomic data. Open questions include the role of alpha-crystallin chaperone activity, protein aggregation mechanisms, and potential therapeutic targets. Gene-edited cell models enable functional validation of mutations and screening for modulators.

Although cataract is not a cancer, the molecular pathways involved in lens opacification share similarities with protein aggregation diseases. Key pathways include:

• • Protein Folding and Chaperone System: Alpha-crystallins (CRYAA, CRYAB) act as molecular chaperones, preventing protein aggregation. Mutations disrupt this function, leading to aggregation.
• • Oxidative Stress Response: Reactive oxygen species (ROS) damage lens proteins, and impaired antioxidant defense contributes to cataract formation.
• • Apoptosis and Autophagy: Lens epithelial cell death and impaired clearance of damaged proteins are implicated.
• • Calcium Signaling: Dysregulation of calcium homeostasis can trigger calpain activation and protein degradation.

Data from ClinVar and literature (e.g., Shiels et al., 2010).

Key signaling networks involved in lens development and cataract pathogenesis include:

• • Wnt/β-catenin Pathway: Regulates lens epithelial cell proliferation and differentiation. Aberrant activation can lead to abnormal fiber cell differentiation.
• • FGF Signaling: Essential for lens fiber cell differentiation; dysregulation affects cell survival.
• • TGF-β Pathway: Involved in epithelial-mesenchymal transition (EMT) and fibrosis, contributing to posterior capsule opacification.
• • PI3K/AKT Pathway: Promotes cell survival; oxidative stress can inhibit this pathway, leading to apoptosis.
• • MAPK/ERK Pathway: Mediates growth factor signals; chronic activation may cause abnormal proliferation.

Organoids derived from human pluripotent stem cells (iPSCs) can recapitulate lens development and are useful for studying early events. They can be gene-edited to introduce CRYAA mutations and used for drug screening.

Animal models for cataract research include:

• • Genetically Engineered Mouse Models (GEMMs): Knock-in mice carrying CRYAA mutations (e.g., R49C) develop cataracts and are used to study pathogenesis.
• • Induced Models: Administration of chemicals (e.g., naphthalene, selenite) induces oxidative stress and cataract formation in rodents.
• • Zebrafish Models: Transgenic zebrafish with mutant crystallins show lens opacification, allowing high-throughput screening.
• • Patient-Derived Xenografts (PDX): Not applicable for cataract, but lens tissue explants can be used.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific CRYAA mutations, such as knockout (KO) or knock-in (KI) of pathogenic variants. These models are invaluable for studying the molecular consequences of mutations in a controlled genetic background. For example:

• • CRYAA Knockout Cell Lines: Loss of alpha-crystallin A leads to increased protein aggregation and susceptibility to stress, mimicking loss-of-function mutations.
• • CRYAA R49C Knock-In Cell Lines: This missense mutation causes dominant-negative effects, leading to chaperone dysfunction and aggregation.

These sequence-verified models are commercially available from various sources, accelerating research by providing consistent, reproducible tools. They can be used for high-content screening, mechanistic studies, and target validation.

Gene-edited cell lines are used to validate the functional impact of CRYAA mutations. For instance, CRISPR knockout of CRYAA in lens epithelial cells leads to increased sensitivity to oxidative stress and accumulation of unfolded proteins. Knock-in of specific mutations (e.g., R49C) can confirm their pathogenicity and provide a platform for studying protein aggregation. These models help identify modifier genes and downstream effectors.

Isogenic pairs (wild-type vs. mutant) are used for high-throughput drug screening to identify compounds that prevent protein aggregation or enhance chaperone activity. For example, small molecules that upregulate heat shock proteins or act as chemical chaperones can be tested. Additionally, these models can be used to study resistance to oxidative stress and evaluate potential therapeutic interventions.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, selectively kill cells with CRYAA mutations. This approach can reveal novel therapeutic targets. Additionally, gene-edited cells can be used to identify biomarkers of cataract progression by analyzing secretomes or transcriptomes.